Emmaus Life Sciences, Inc. (EMMA)
OTCMKTS · Delayed Price · Currency is USD
0.0352
-0.0055 (-13.51%)
At close: Oct 29, 2026
Emmaus Life Sciences Revenue
Emmaus Life Sciences had revenue of $6.32M in the quarter ending June 30, 2026, with 124.28% growth. This brings the company's total for the last twelve months to $15.53M, up 10.98% year-over-year. In the year 2025, Emmaus Life Sciences had annual revenue of $12.45M, down -25.22%. That makes Emmaus Life Sciences the 35,211th largest company in the world by revenue and 4,640th in the United States.
Revenue (ttm)
15.53M
Revenue Growth
+10.98%
P/S Ratio
0.16
Revenue / Employee
470.61K
Employees
33
Market Cap
2.47M
Revenue by Geography
- United States 9.05M 72.7%
- International 3.18M 25.5%
- Other 225.00K 1.8%
Fiscal year ended Dec 31, 2025 See the full Emmaus Life Sciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 12.45M | -4.20M | -25.22% |
| Dec 31, 2024 | 16.65M | -12.94M | -43.73% |
| Dec 31, 2023 | 29.60M | 11.21M | 60.94% |
| Dec 31, 2022 | 18.39M | -2.22M | -10.77% |
| Dec 31, 2021 | 20.61M | -2.56M | -11.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CASI Pharmaceuticals | 20.11M |
| BioAtla | 8.50M |
| Vaccinex | 601.00K |
| GPL Holdings | 376.54K |
| Enzolytics | 46.59K |
Emmaus Life Sciences News
- 2 months ago - Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer - Business Wire
- 2 months ago - Emmaus Life Sciences Reports Quarterly Financial Results - Business Wire
- 7 months ago - Emmaus Life Sciences Reports Annual Financial Results - Business Wire
- 10 months ago - Emmaus Life Sciences enters license, distribution agreement with NeoImmuneTech - TheFly
- 10 months ago - Emmaus Life Sciences Announces Strategic Transaction - Business Wire
- 1 year ago - Emmaus Life Sciences receives FDA approval for Endari label changes - TheFly
- 1 year ago - Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements - PRNewsWire
- 1 year ago - Emmaus Life Sciences Reports Improved Quarterly Financial Results - PRNewsWire